Active Ingredient(s): Asciminib Hydrochloride
FDA Approved: * October 29, 2021
Pharm Company: * NOVARTIS
Category: Cancer

Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).[1][2][3] Asciminib is a protein kinase inhibitor.[1] The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea.[2] Asciminib was approved for medical use in the United States in October 2021.&a... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Scemblix 20 mg Oral Tablet, Film Coated
NDC: 0078-1091
Novartis Pharmaceuticals Corporation
Scemblix 40 mg Oral Tablet, Film Coated
NDC: 0078-1098
Novartis Pharmaceuticals Corporation